From 11 July 2022, more Australians at higher risk of developing severe COVID-19 will be able to access oral antiviral treatments following new recommendations from the Pharmaceutical Benefits Advisory Committee.

Most cases of COVID-19 are mild and can be managed at home. Some people who are at higher risk may need specific antiviral treatments prescribed by their healthcare provider.

Learn more about who is eligible for COVID-19 treatments by clicking on this link